128 F. J. Swartling downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res. 2006;66:8655–61. 7. Zindy F, Knoepﬂer PS, Xie S, Sherr CJ, Eisenman RN, Roussel MF. N-Myc and the cyclin-dependent kinase inhibi- tors p18Ink4c and p27Kip1 coordinately regulate cerebellar development. Proc Natl Acad Sci USA. 2006;103:11579–83. 8. Wey A, Knoepﬂer PS. c-myc and N-myc promote active stem cell metabolism and cycling as architects of the developing brain. Oncotarget. 2010;1:120–30. 9. Fults D, Pedone C, Dai C, Holland EC. MYC expression promotes the proliferation of neural progenitor cells in culture and in vivo. Neoplasia. 2002;4:32–9. 10. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63:441–9. 11. Pﬁster S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al. Outcome prediction in pediatric medullo- blastoma based on DNA copy-number aberrations of chro- mosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009;27:1627–36. 12. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, et al. MYCC and MYCN oncogene ampliﬁ- cation in medulloblastoma. A ﬂuorescence in situ hybridiza- tion study on parafﬁn sections from the Children’s Oncology Group. Arch Pathol Lab Med. 2002;126:540–4. 13. Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell. 2008;14:135–45. 14. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be deﬁned by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4:e7752. 15. Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, et al. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinico- pathologic and genetic study of 53 cases. Brain Pathol. 2009; 19:81–90. 16. Rouah E, Wilson DR, Armstrong DL, Darlington GJ. N-myc ampliﬁcation and neuronal differentiation in human primitive neuroectodermal tumors of the central nervous system. Can- cer Res. 1989;49:1797–801. 17. Browd SR, Kenney AM, Gottfried ON, Yoon JW, Walterhouse D, Pedone CA, et al. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res. 2006; 66:2666–72. 18. Kessler JD, Hasegawa H, Brun SN, Yang ZJ, Dutton JW, Wang F, et al. N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev. 2009;23: 157–70. 19. Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, et al. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res. 2007;67:2676–84. 20. Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010;24:1059–72. 21. Momota H, Shih AH, Edgar MA, Holland EC. C-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene. 2008;27:4392–401. 22. Lassman AB, Dai C, Fuller GN, Vickers AJ, Holland EC. Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biol. 2004;1:157–63. 23. Lee JS, Lee HJ, Moon BH, Song SH, Lee MO, Shim SH, et al. Generation of Cancerous neural stem cells forming glial tumor by oncogenic stimulation. Stem Cell Rev. 2011;Jul14Epub ahead of print. 24. Meyer N, Penn LZ. Reﬂecting on 25 years with MYC. Nat Rev Cancer. 2008;8:976–90. 25. Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro Oncol. 1999;1:205–11. 26. Gilbertson RJ. Medulloblastoma: signalling a change in treat- ment. Lancet Oncol. 2004;5:209–18. 27. Eberhart CG, Burger PC. Anaplasia and grading in medul- loblastomas. Brain Pathol. 2003;13:376–85. 28. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al. Genomics identiﬁes medulloblastoma sub- groups that are enriched for speciﬁc genetic alterations. J Clin Oncol. 2006;24:1924–31. 29. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated genomics identiﬁes ﬁve medul- loblastoma subtypes with distinct genetic proﬁles, pathway signatures and clinicopathological features. PLoS One. 2008; 3:e3088. 30. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medullo- blastoma identiﬁes a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29:1424–30. 31. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29: 1408–14. 32. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2011;[Epub ahead of print]. 33. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006;5:2666–70. 34. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: clinicopathological corre- lates of SHH, WNT, and non-SHH/WNT molecular sub- groups. Acta Neuropathol. 2011;121:381–96. 35. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010;468:1095–9. 36. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;66: 7445–52. 37. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar- Thomas A, Kocak M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: A pediatric brain tumor consortium study. J Clin Oncol. 2011;29:3529–34. 38. Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, et al. Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene. 2010;29:3865–72. 39. Julian E, Dave RK, Robson JP, Hallahan AR, Wainwright BJ. Canonical Notch signaling is not required for the growth of